X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs PFIZER - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES PFIZER PIRAMAL ENTERPRISES/
PFIZER
 
P/E (TTM) x 8.3 33.5 24.9% View Chart
P/BV x 1.5 4.7 31.5% View Chart
Dividend Yield % 1.1 0.7 151.7%  

Financials

 PIRAMAL ENTERPRISES   PFIZER
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-18
PFIZER
Mar-18
PIRAMAL ENTERPRISES/
PFIZER
5-Yr Chart
Click to enlarge
High Rs3,0832,365 130.4%   
Low Rs1,9021,625 117.0%   
Sales per share (Unadj.) Rs589.7430.3 137.1%  
Earnings per share (Unadj.) Rs284.078.7 360.9%  
Cash flow per share (Unadj.) Rs310.593.2 333.2%  
Dividends per share (Unadj.) Rs25.0020.00 125.0%  
Dividend yield (eoy) %1.01.0 100.0%  
Book value per share (Unadj.) Rs1,467.0586.5 250.1%  
Shares outstanding (eoy) m180.2745.75 394.0%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x4.24.6 91.2%   
Avg P/E ratio x8.825.3 34.6%  
P/CF ratio (eoy) x8.021.4 37.5%  
Price / Book Value ratio x1.73.4 50.0%  
Dividend payout %8.825.4 34.6%   
Avg Mkt Cap Rs m449,33291,271 492.3%   
No. of employees `0006.82.6 260.2%   
Total wages/salary Rs m19,8813,143 632.6%   
Avg. sales/employee Rs Th15,535.67,484.8 207.6%   
Avg. wages/employee Rs Th2,905.41,195.0 243.1%   
Avg. net profit/employee Rs Th7,482.51,369.1 546.5%   
INCOME DATA
Net Sales Rs m106,31019,685 540.1%  
Other income Rs m2,5951,143 227.1%   
Total revenues Rs m108,90620,828 522.9%   
Gross profit Rs m51,5995,003 1,031.4%  
Depreciation Rs m4,773663 720.5%   
Interest Rs m29,7834 709,119.0%   
Profit before tax Rs m19,6385,479 358.4%   
Minority Interest Rs m2,8010-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-28,7641,878 -1,531.3%   
Profit after tax Rs m51,2033,601 1,422.0%  
Gross profit margin %48.525.4 191.0%  
Effective tax rate %-146.534.3 -427.3%   
Net profit margin %48.218.3 263.3%  
BALANCE SHEET DATA
Current assets Rs m118,15424,167 488.9%   
Current liabilities Rs m462,2609,544 4,843.3%   
Net working cap to sales %-323.774.3 -435.7%  
Current ratio x0.32.5 10.1%  
Inventory Days Days2755 48.2%  
Debtors Days Days4729 162.1%  
Net fixed assets Rs m113,7279,514 1,195.4%   
Share capital Rs m361458 78.8%   
"Free" reserves Rs m264,09326,375 1,001.3%   
Net worth Rs m264,45426,832 985.6%   
Long term debt Rs m242,20625 968,824.4%   
Total assets Rs m726,83436,900 1,969.8%  
Interest coverage x1.71,305.5 0.1%   
Debt to equity ratio x0.90 98,298.8%  
Sales to assets ratio x0.10.5 27.4%   
Return on assets %11.19.8 114.1%  
Return on equity %19.413.4 144.3%  
Return on capital %10.320.4 50.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,11022 67,455.4%   
Fx outflow Rs m4,2981,489 288.7%   
Net fx Rs m10,813-1,466 -737.4%   
CASH FLOW
From Operations Rs m-159,6663,318 -4,812.1%  
From Investments Rs m-17,677-2,383 741.8%  
From Financial Activity Rs m186,503-1,104 -16,901.0%  
Net Cashflow Rs m9,364-169 -5,557.4%  

Share Holding

Indian Promoters % 52.9 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 4.0 7.5 53.3%  
FIIs % 26.6 4.9 542.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 23.7 69.6%  
Shareholders   93,274 85,207 109.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   GLENMARK PHARMA  FULFORD INDIA  MERCK LTD  DIVIS LABORATORIES  UNICHEM LAB  

Compare PIRAMAL ENTERPRISES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.

Related Views on News

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY19); Net Profit Up 59.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 59.3% YoY). Sales on the other hand came in at Rs 31 bn (up 24.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Nov 15, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS